DrLuke Howard

Pulmonary Hypertension Clinical Trials
Early phase studies examining new targets with novel clinical end-points. Current and recent examples include:

Chief Investigator of randomised trial of intravenous iron in idiopathic pulmonary arterial hypertension (IPAH)
Chief Investigator (UK) for safety and efficacy study of pulmonary artery denervation with high-energy ultrasound
Open-label dose ranging trial of dicholoracetate in IPAH
Anti-IL-6 in IPAH and connective-tissue PAH
Chief Investigator (UK) in Phase II study of Macitentan in chronic thromboembolic PH
Intravenous apelin on resting and exercise haemodynamics in PAH
Late phase with novel end-points:

Chief Investigator (UK) for activity-based exploratory outcome measures in randomised trial of IP3 agonist in PAH
Pulmonary Embolism
Physiological impact of chronic thromboembolic disease
Genetic and molecular profiling of pulmonary embolism
Cardiopulmonary Physiology
Physiological phenotyping of pulmonary vascular diseases with exercise, haemodynamics and wave-intensity analysis
Using exercise endpoints in clinical trials